Jump to content

Outpatient parenteral antibiotic therapy

From Wikipedia, the free encyclopedia
Outpatient parenteral antibiotic therapy
Other namesOPAT

Outpatient parenteral antibiotic therapy (OPAT) is used to administer non-oral antibiotics (usually intravenously) without the need for ongoing hospitalisation. OPAT is particularly useful for people who are not severely ill but do require a prolonged course of treatment that cannot be given in oral form.[1] OPAT is being increasingly adopted as part of antimicrobial stewardship programs; it can reduce length of stay, costs and adverse events while improving quality of life.[2] OPAT can be administered in an outpatient facility (including a provider's office, infusion center or day hospital) or at a patient's residence using an infusion pump, such as an elastomeric pump.[3][4]

Common antimicrobials

[edit]

Common antimicrobials used for continuous infusion are shown below:[5]

Antibiotic Stability at 25 °C Diluent Existing data in elastomeric pumps
cefepime 24 hours normal saline Yes
ceftazidime 48 hours normal saline Yes
clindamycin 16 days dextrose 5% No
flucloxacillin 24 hours normal saline Yes
fosfomycin 24 hours water for injection No
oxacillin 24 hours normal saline No
benzylpenicillin potassium 24–48 hours ringer acetate Yes
benzylpenicillin sodium 12–24 hours normal saline Yes
piperacillin/tazobactam 24 hours normal saline Yes
vancomycin 7 days normal saline Yes

Before starting beta-lactams and vancomycin infusion, it is advisable to administer a loading dose in order to reduce time to reach target concentrations[6][7]

References

[edit]
  1. ^ Chapman, A. L. N. (26 March 2013). "Outpatient parenteral antimicrobial therapy". BMJ. 346 (mar26 1): f1585. doi:10.1136/bmj.f1585. PMID 23532865. S2CID 38761363.
  2. ^ Voumard, Rachel; Gardiol, Céline; André, Pascal; Arensdorff, Lyne; Cochet, Camille; Boillat-Blanco, Noémie; Decosterd, Laurent; Buclin, Thierry; de Vallière, Serge (2018-09-01). "Efficacy and safety of continuous infusions with elastomeric pumps for outpatient parenteral antimicrobial therapy (OPAT): an observational study". Journal of Antimicrobial Chemotherapy. 73 (9): 2540–2545. doi:10.1093/jac/dky224. ISSN 0305-7453. PMID 29982449.
  3. ^ Docherty T, Schneider JJ, Cooper J (December 2020). "Clinic- and Hospital-Based Home Care, Outpatient Parenteral Antimicrobial Therapy (OPAT) and the Evolving Clinical Responsibilities of the Pharmacist". Pharmacy. 8 (4): 233. doi:10.3390/pharmacy8040233. PMC 7768382. PMID 33297356.
  4. ^ Spencer-Jones J, Luxton T, Bond SE, Sandoe J (August 2023). "Feasibility, Effectiveness and Safety of Elastomeric Pumps for Delivery of Antibiotics to Adult Hospital Inpatients-A Systematic Review". Antibiotics. 12 (9): 1351. doi:10.3390/antibiotics12091351. PMC 10525832. PMID 37760648. Elastomeric infusion pumps (EMPs) have been implemented in many fields, including analgesia, chemotherapy and cardiology. Their application in antimicrobials is mainly limited to the outpatient setting, but with a need to optimise inpatient antimicrobial treatment, the use of EMPs presents a potential option.
  5. ^ Di Bella, Stefano; Beović, Bojana; Fabbiani, Massimiliano; Valentini, Michael; Luzzati, Roberto (2020-07-10). "Antimicrobial Stewardship: From Bedside to Theory. Thirteen Examples of Old and More Recent Strategies from Everyday Clinical Practice". Antibiotics. 9 (7): 398. doi:10.3390/antibiotics9070398. ISSN 2079-6382. PMC 7399849. PMID 32664288.
  6. ^ Roberts, Jason A.; Kirkpatrick, Carl M.J.; Roberts, Michael S.; Dalley, Andrew J.; Lipman, Jeffrey (February 2010). "First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis". International Journal of Antimicrobial Agents. 35 (2): 156–163. doi:10.1016/j.ijantimicag.2009.10.008. PMID 20018492.
  7. ^ Waineo, M. F.; Kuhn, T. C.; Brown, D. L. (June 2015). "The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion". Journal of Clinical Pharmacy and Therapeutics. 40 (3): 259–265. doi:10.1111/jcpt.12270. PMID 25865426.